The enzyme inhibitors industry in emerging markets has significant potential, in contrast to mature markets where growth is significantly slower. Having accurate market data and analysis is essential to companies that wish to compete on the global stage. With premium market research from the worlds leading publishers, Global Information Inc. helps businesses stay on the cutting edge with the best forecasts, research, and analyses.
Global Information is pleased to announce the immediate availability of three significant new reports on Enzyme Inhibitors.
Global Markets for Enzyme Inhibitors -- Focus on Europe
Global Markets for Enzyme Inhibitors -- Focus on US
Global Markets for Enzyme Inhibitors -- Focus on Emerging Markets
The overall goal of this series is to provide a comprehensive understanding of the current and future characteristics for enzyme inhibitors, which include proton pump inhibitors (PPIs), protease inhibitors, reverse transcriptase inhibitors, kinase inhibitors, statins, aromatase inhibitors, phosphodiesterase type 5 (PDE5) inhibitors, neuraminidase inhibitors, and angiotensin-converting enzyme (ACE) inhibitors.
Each report offers Market sizes with 5-year forecasts from 2011 to 2016 for enzyme inhibitors in the pharmaceutical and biotechnology industry. These include market projections and market shares as well as a technology SWOT analysis.
Due to patent expiry, the US Enzyme Inhibitors market declined in 2011, down to $44.9 billion from $46.8 billion in 2010. The US market is expected to recover slowly to $47.4 billion by 2016, at a CAGR of 1.1%. The US kinase inhibitors market fell to $10.4 billion in 2011 from $10.8 billion in 2010. This market is expected to recover to $11.6 billion by 2016, a CAGR of 2.2%.
European Markets held mostly flat in 2011. The European market for enzyme inhibitors was $32 billion in 2010 and rose to $32.4 billion in 2011, and will rise at a CAGR of 3.6% to reach nearly $38.7 billion by 2016. European sales of kinase inhibitors were also mostly flat, at $9.2 billion in 2010 and $9.4 billion in 2011, but are forecast to reach $11.6 billion by 2016 at a CAGR of 4.4%.
The greatest potential by far lies in the emerging markets of India, China, Japan, Korea, Taiwan, Canada, Africa, Australia and New Zealand. Enzyme inhibitors in these markets are estimated at $25.6 billion in 2010 and $27.2 billion in 2011, expected to rise at a CAGR of 8.7% and reach nearly $41.3 billion through 2016. Kinase inhibitors in particular were $8.2 billion in 2010 and $9.3 billion in 2011, set to grow at a CAGR of 13% to reach nearly $17.1 billion by 2016.
An Executive Summary of this analysis and a free sample of each report is available from Global Information, Inc: